Edition:
United States

Regeneron Pharmaceuticals Inc (REGN.OQ)

REGN.OQ on NASDAQ Stock Exchange Global Select Market

418.84USD
18 Jan 2019
Change (% chg)

$1.46 (+0.35%)
Prev Close
$417.38
Open
$420.42
Day's High
$420.48
Day's Low
$410.00
Volume
303,340
Avg. Vol
274,687
52-wk High
$420.48
52-wk Low
$281.89

Select another date:

Mon, Jan 7 2019

Photo

U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

UPDATE 4-U.S. top court rejects Amgen over cholesterol medication patent fight

WASHINGTON, Jan 7 Amgen Inc on Monday lost its bid at the U.S. Supreme Court to overturn a ruling that kept the Regeneron Pharmaceuticals Inc and Sanofi SA cholesterol-lowering drug Praluent on the market, but the patent dispute among the rival drugmakers will continue in another trial.

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

PARIS Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

CORRECTED-UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal

PARIS, Jan 7 Sanofi will pay Regeneron some $462 million in a revision of their deal in immuno-oncology, a growing sector in healthcare research which aims to help the body's own immune system fight cancer.

Drugmakers Sanofi, Regeneron restructure immuno-oncology deal

PARIS, Jan 7 Healthcare companies Sanofi and Regeneron have restructured an earlier deal in the immuno-oncology sector, which will result in Sanofi paying its U.S. partner some $582 million.

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

UPDATE 1-Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator has given more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies

PARIS, Nov 6 The U.S. Food & Drug Administration (FDA) regulator gave more positive feedback on the Dupixent eczema treatment being developed by drugmakers Sanofi and Regeneron, the companies said on Tuesday.

Regeneron wins dismissal of willfulness claim in Eylea patent dispute

Regeneron Pharmaceuticals Inc has won dismissal of Novartis AG's claim that two of its biologic drugs willfully infringed a now-expired patent on gene expression technology.

FDA declines to approve pre-filled syringe version of Regeneron's Eylea

Regeneron Pharmaceuticals Inc said on Thursday the U.S. Food and Drug Administration declined to approve a pre-filled syringe version of its blockbuster eye drug Eylea, and has sought additional information regarding its manufacturing and supply processes.

Select another date: